中国中西医结合杂志
中國中西醫結閤雜誌
중국중서의결합잡지
CHINESE JOURNAL OF INTEGRATED TRADITIONAL AND WESTERN MEDICINE
2001年
2期
108-110
,共3页
心肌梗死%血栓溶解疗法%尿激酶%99m锝-甲氰基异丁基晴心肌灌注断层显像%参麦注射液
心肌梗死%血栓溶解療法%尿激酶%99m锝-甲氰基異丁基晴心肌灌註斷層顯像%參麥註射液
심기경사%혈전용해요법%뇨격매%99m득-갑청기이정기청심기관주단층현상%삼맥주사액
目的：用99m锝-甲氰基异丁基晴心肌灌注断层显像(SPECT)，评价参麦注射液对急性心肌梗死(AMI)尿激酶(UK)溶栓治疗再灌注心肌保护作用的临床疗效。方法：537例AMI患者随机分为两组，参麦组(292例)采用UK溶栓疗法和参麦注射液治疗，对照组(245例)只使用UK溶栓疗法。于溶栓治疗后第7日进行SPECT检测。对两组心肌缺血面积(IMA)和左室射血分数(EF)的变化进行对比研究。结果：参麦组和对照组梗塞相关血管(IRA)再通率之间差异无显著性(分别为72.26%、72.65%，P＞0.05)。参麦组IRA再通患者(211例)的IMA显著低于对照组IRA再通患者(178例，P＜0.01)。参麦组IRA未通患者(81例)的IMA与对照组(67例)比较，亦显著降低(P＜0.05)。参麦组EF显著高于对照组(P＜0.01)。结论：在AMIUK溶栓治疗早期使用参麦注射液可显著缩减IMA，提高EF。参麦注射液对AMI溶栓再灌注心肌具有良好的保护作用。
目的：用99m锝-甲氰基異丁基晴心肌灌註斷層顯像(SPECT)，評價參麥註射液對急性心肌梗死(AMI)尿激酶(UK)溶栓治療再灌註心肌保護作用的臨床療效。方法：537例AMI患者隨機分為兩組，參麥組(292例)採用UK溶栓療法和參麥註射液治療，對照組(245例)隻使用UK溶栓療法。于溶栓治療後第7日進行SPECT檢測。對兩組心肌缺血麵積(IMA)和左室射血分數(EF)的變化進行對比研究。結果：參麥組和對照組梗塞相關血管(IRA)再通率之間差異無顯著性(分彆為72.26%、72.65%，P＞0.05)。參麥組IRA再通患者(211例)的IMA顯著低于對照組IRA再通患者(178例，P＜0.01)。參麥組IRA未通患者(81例)的IMA與對照組(67例)比較，亦顯著降低(P＜0.05)。參麥組EF顯著高于對照組(P＜0.01)。結論：在AMIUK溶栓治療早期使用參麥註射液可顯著縮減IMA，提高EF。參麥註射液對AMI溶栓再灌註心肌具有良好的保護作用。
목적：용99m득-갑청기이정기청심기관주단층현상(SPECT)，평개삼맥주사액대급성심기경사(AMI)뇨격매(UK)용전치료재관주심기보호작용적림상료효。방법：537례AMI환자수궤분위량조，삼맥조(292례)채용UK용전요법화삼맥주사액치료，대조조(245례)지사용UK용전요법。우용전치료후제7일진행SPECT검측。대량조심기결혈면적(IMA)화좌실사혈분수(EF)적변화진행대비연구。결과：삼맥조화대조조경새상관혈관(IRA)재통솔지간차이무현저성(분별위72.26%、72.65%，P＞0.05)。삼맥조IRA재통환자(211례)적IMA현저저우대조조IRA재통환자(178례，P＜0.01)。삼맥조IRA미통환자(81례)적IMA여대조조(67례)비교，역현저강저(P＜0.05)。삼맥조EF현저고우대조조(P＜0.01)。결론：재AMIUK용전치료조기사용삼맥주사액가현저축감IMA，제고EF。삼맥주사액대AMI용전재관주심기구유량호적보호작용。
Objective: To evaluate the myocardial protecting effect ofShenmai injection (SMI) against ischemia/reperfusion injury in thrombolytic therapy with urokinase (UK) for acute myocardial infarction patients by 99m Tc-MIBI myocardial imaging (SPECT). Methods: Five hundred and thirty-seven patients were randomly divided into two groups. The SMI group (n＝292) was treated with thrombolytic treatment plus SMI and the control group (n=245) with thrombolytic treatment only. Single photon emission computerized tomography (SPECT) was carried out on the 7th day after thrombolysis to determine the ischemic myocardial area (IMA) and ejection fraction (EF) in both groups and compared. Results: The reperfusion rate of infarction related area (IRA) in the two groups was not different significantly (72.26% vs 72.65%, P＞0.05). The IMA in patients of the SMI group, no matter with or without reperfused IRA (211 cases and 81 cases) respectively, was significantly lower than that in the control group (178 cases and 67 cases) respectively, P＜0.01 and P＜0.05 respectively. The EF value in the SMI group was significantly higher than that in the control group (P＜0.01). Conclusion: Using SMI in early stage of thrombolytic treatment in acute myocardial infarction could significantly reduce IMA and increase EF. SMI showed good protective effect against myocardial ischemia/reperfusion injury in thrombolytic treatment.
